New Data Demonstrates Economic Benefit of Exagen’s AVISE® Lupus Test for Payors
October 12 2020 - 4:05PM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, today announced the publication of a study
evaluating the economic benefits AVISE® Lupus testing, titled
“Evaluation of the Economic Benefit of Earlier Systemic Lupus
Erythematosus (SLE) Diagnosis using a Multivariate Assay Panel
(MAP)” in ACR Open Rheumatology.
Lead author Dr. Ann Clarke, Professor and Arthritis Society
Chair in Rheumatic Diseases at the Cumming School of Medicine,
University of Calgary, stated, “It is widely known there are
varying limitations to the decades-old standard diagnostic tests
for SLE, and these findings support the clinical need for an
improved SLE diagnostic test.”
Key advancements and findings:
- First ever evaluation of the
economics of diagnosing SLE with AVISE® Lupus (MAP) compared to
Standard Diagnostic Laboratory Tests (SDLTs) in a hypothetical
cohort of 1,000 suspected SLE patients
- Over the four-year time horizon
AVISE Lupus demonstrated an estimated total direct cost savings of
$1,991,152, or $1,991 per patient
- Year 1 savings of $655,403, or $655
per eligible patient, with the use of AVISE® Lupus, which aligns
with early benefit to health plans looking for savings in the first
year
“We are proud to provide in collaboration with leading health
economic experts the first ever published data demonstrating the
economic benefit of AVISE® Lupus compared to SDLTs,” said Ron
Rocca, President and CEO of Exagen. “Patients suffering from SLE
face significant health disparities, and it is well established
that earlier diagnosis often leads to improved patient outcomes.
This study quantifies the added economic benefit of early
intervention in the treatment of this hard-to-diagnose
disease.”
The diagnosis of SLE is complicated and it takes on average over
six years after seeing more than four health care providers; AVISE®
Lupus provides a valuable tool to accelerate the diagnosis process.
The AVISE® Lupus algorithmic two-tier index utilizes Exagen’s
proprietary Cell-Bound Complement Activation Products (CB-CAPs),
combined with SLE associated markers, to provide a diagnostic tool
with greater sensitivity over C3/C4 and anti-dsDNA and greater
specificity over antinuclear antibody (ANA).
ACR Open Rheumatology is a peer-reviewed, open access official
journal of the American College of Rheumatology. It publishes
specialized articles reporting on original investigations of
various aspects of rheumatology-related research including basic
science, clinical science, epidemiology, health outcomes, and
education, as well as reviews and commentaries in the field of
rheumatology and related disciplines.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune related diseases,
including rheumatoid arthritis and lupus. For further information
please visit www.exagen.com.
Forward Looking Statements
Exagen cautions you that statements in this press release that
are not a description of historical facts are forward-looking
statements. These statements are based on the Company's current
beliefs and expectations. Such forward-looking statements include,
but are not limited to, statements regarding the the potential for
AVISE® Lupus to provide added economic benefit to payors and lead
to additional test adoption; and the ability of the AVISE® Lupus
test to help physicians with earlier diagnosis often leading to
improved patient outcomes. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: the COVID-19 pandemic may continue to adversely affect
our business, financial condition and results of operations;
Exagen’s commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payers
and others in the medical community; third party payers not
providing coverage and adequate reimbursement for the company’s
testing products or promoted therapeutics; the company’s ability to
obtain and maintain intellectual property protection for its
testing products; regulatory developments affecting the company’s
business; risks associated with maintaining third-party
partnerships and Exagen’s performance thereunder; and other risks
described in the Company’s prior press releases and in the
Company’s filings with the Securities and Exchange Commission,
including under the heading "Risk Factors" in the company’s Annual
Report on Form 10-K and any subsequent filings with the SEC. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and we
undertake no obligation to revise or update this press release to
reflect events or circumstances after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, which is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
CONTACTS:
Investors
Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com
646.677.1838
Company Contact
Exagen Inc.
Kamal Adawi, Chief Financial Officer
KAdawi@exagen.com
760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024